Professional Documents
Culture Documents
Review Paper
Review Paper
In vivo=in situ
RNA vaccine
-mRNA vaccine 항원을 암호화한 mRNA 를 이용한 vaccine
-항원 발현은 백신 접종동안 성공적으로 전달된 기존 mRNA 전사체의 수에 비례한다.
[11]다시읽기
Post-translation capping enzyme-combined with 2′-O-methyl- transferases, generate Cap 1 structures that mimic
natural eukaryotic mRNAs high capping efficiencies
The co-delivery of immune modulating transcripts, particularly pattern recognition receptors (PRRs)
antagonists, may help mitigate these effects
dsRNA PKR stimulate eIf2(translation initiation) 인산화 inactive translation level down
-cationic lipids, LNPs, polymers, and protamine sulfate, as well as physical methods such as electroporation
be used to deliver RNA therapeutics and vaccines
-pABOL
-ornithine dendrimers
-mannosylated polyethyleneimine
-transamplifying approach
Adjuvant(보조제)적응 면역 강화 + T 세포 반응 유도
SVF replicon
Sequence diversity of the HIV-1 viral Env glycoprotein required for entry into
cells has presented a challenge to vaccine design
VRR
The self-adjuvant effect of saRNAs may augment immunity and novel HIV-1
candidates have shown potential in preclinical models of infection (Table 1). In
2012, to highlight the flexibility of their LNP-formulated replicon, Geall et al.
[81] described the first HIV-1 Env gp140 saRNA vaccine in mice.
Conclusion
-무세포제조 파이프 라인
saRNA 는 항원 서열을 하위 유전자 전사체로 증폭시키고, 이러한 면역 조절
단백질의 세포질에 축적은 특히 만성 감염성 질병에 대한 유전자 면역 전략을
향상시킬 수 있다
RNA modifying